Biotechnology - Biotechnology, Exelixis

Filter

Current filters:

BiotechnologyExelixis

Popular Filters

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

15-12-2014

Genentech, the US biotech subsidiary of Swiss Pharma major Roche Group, has submitted a New Drug Application…

BiotechnologycobimetinibExelixisGenentechOncologyRegulationRocheUSAZelboraf

Exelixis says cabozantinib failed in Ph III prostate cancer trial

Exelixis says cabozantinib failed in Ph III prostate cancer trial

02-09-2014

US biotech firm Exelixis has posted disappointing top-line results from the final analysis of COMET-1,…

BiotechnologycabozantinibExelixisOncologyResearchSwedish Orphan Biovitrum

EU approval for Cometriq in medullary thyroid carcinoma

EU approval for Cometriq in medullary thyroid carcinoma

25-03-2014

The European Commission has approved Cometriq (cabozantinib), a drug for the treatment of adult patients…

BiotechnologyCometriqEuropeExelixisOncologyRegulationSwedish Orphan Biovitrum

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

Exelixis appoints Jeffrey Hessekiel as Executive Vice President and General Counsel

13-02-2014

Exelixis (NASDAQ: EXEL) have announced the appointment of Jeffrey Hessekiel as executive vice president…

BiotechnologyBoardroomExelixisOncologyUSA

SOBI to distribute Exelixis' cancer drug Cometriq in EU

22-02-2013

US biotech firm Exelixis (Nasdaq: EXEL) has entered into a three-year with Swedish Orphan Biovitrum (STO:…

BiotechnologyCometriqEuropeExelixisLicensingOncologySobiSwedish Orphan Biovitrum

FDA approves Exelixis' Cometriq for rare thyroid cancer, as EMA accepts filing

30-11-2012

There were two items of good news yesterday for US drug developer Exelixis' (Nasdaq: EXEL), the first…

AstraZenecaBiotechnologycabozantinibCaprelsaCometriqEuropeExelixisNorth AmericaOncologyPharmaceuticalRegulation

Back to top